Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial
Cancer Medicine · 2023-03 · 12 (5) · 6190-6199
DOI: 10.1002/cam4.5351 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, online erschienen am 18.10.2022. Verfasst von Ilana Graetz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Mobile Applications, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background
Cancer treatment requires substantial demands on patients and their caregivers. Mobile apps can provide support for self‐management during oncology treatment, but few have been rigorously evaluated.
Methods
A 3‐month randomized controlled trial was conducted at a large cancer center to evaluate the efficacy of an app (LivingWith®) that provides self‐management support during cancer treatment on quality of life and health care utilization. Patients in chemotherapy treatment were randomized into the intervention ( n = 113) and control group ( n = 111). Intervention group participants agreed to use the app weekly for 3 months, and all participants completed a survey at enrollment and after 3 months to evaluate changes in quality of life and health care utilization.
Results
Retention rate was 75.4% with 169 participants completing the follow‐up survey. The intervention group reported 0.74 fewer medical office visits ( p = 0.043) and 0.24 fewer visits with a mental health professional ( p = 0.061) during the 3 and month intervention compared with controls. There were no significant changes by study group in quality of life, or emergency room and urgent care visits. Among intervention participants, 75.3% reported using the app and on average, used it 11.7 times during the 3‐month intervention. Reasons for not using the app among intervention participants included lack of time, lack of interest in apps, and usability challenges. Conclusions and Relevance Apps are inexpensive and scalable tools that can provide additional support for individuals coping with complex cancer treatments. This trial provides evidence that a well‐designed oncology support app used during chemotherapy resulted in fewer clinic visits. Still, nearly a quarter of participants randomized to the intervention arm reported never using the app due to personal preference and usability challenges, which points to future opportunities for calibrating target user population and improving user‐centered design. Clinicaltrials.gov identifier: NCT04331678.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- West Cancer Center and Research Institute, Germantown, Tennessee, USA.
- Renown Institute for Cancer, Reno, Nevada, USA.
ORCID-Profile: Ilana Graetz, Xin Hu, Lee S Schwartzberg
Förderung
- Pfizer
Zitieren
APA
Graetz, I., Hu, X., Curry, A. N., Robles, A., Vidal, G. A., & Schwartzberg, L. S. (2023). Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial. Cancer Medicine, 12(5), 6190-6199. https://doi.org/10.1002/cam4.5351
Vancouver
Graetz I, Hu X, Curry AN, Robles A, Vidal GA, Schwartzberg LS. Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial. Cancer Medicine. 2023;12(5):6190-6199. doi:10.1002/cam4.5351
BibTeX
@article{Graetz2023,
author = {Graetz, Ilana and Hu, Xin and Curry, Andrea N and Robles, Andrew and Vidal, Gregory A and Schwartzberg, Lee S},
title = {Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trial},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {5},
pages = {6190--6199},
doi = {10.1002/cam4.5351}
}
EUVIMED